TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35353163
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol (10-μg)
Study: 34483029
Drug: Ivermectin 24
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 24 mg
Study: 34483029
Drug: Ivermectin 12
Normalized name: Ivermectin 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 12 mg
Study: 34483029
Drug: Ivermectin 24
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 24 mg and 12 mg
Study: 35599913
Drug: Greek yogurt
Normalized name: Greek pitch
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek yogurt (GY), 3 servings/day, 115 kcal, 17 g protein, 11.5 g carbohydrates
Study: 35599913
Drug: Isoenergetic carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic carbohydrate control (CHO), 3 servings/day, 115 kcal, 0.04 g protein, 28.6 g carbohydrates
Study: 32330277
Drug: High-dosage CQ
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage CQ (600 mg CQ twice daily for 10 days)
Study: 32330277
Drug: Low-dosage CQ
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage CQ (450 mg twice daily on day 1 and once daily for 4 days)
Study: 32330277
Drug: High-dosage CQ
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage CQ
Study: 32330277
Drug: Low-dosage CQ
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage CQ
Study: 39085664
Drug: Usual Treatment
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Treatment (UT)
Study: 32967528
Drug: Seven daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven daily sessions of mindfulness training
Study: 32563253
Drug: Amaranth seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaranth seed oil (ASO) 20 mL/d
Study: 32563253
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (RSO) 20 mL/d
Study: 32236104
Drug: Combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination
Study: 36343646
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of hypertonic saline
Study: 36343646
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of dornase alfa
Study: 32594305
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole
Study: 33143647
Drug: Arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic microfracture with atelocollagen augmentation (group 1, n = 31)
Study: 33143647
Drug: Arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic microfracture with atelocollagen augmentation (group 1)
Study: 33947827
Drug: 10-week individual-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-week individual-based multimodal program of task-oriented exercises integrated with cognitive-behavioral therapy
Study: 32838584
Drug: Vaccine development
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine development efforts against sexually transmitted viruses (STVs)
Study: 32838584
Drug: Various approaches
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various approaches for improving prophylactic or therapeutic vaccines
Study: 34021038
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rivaroxaban 2.5 mg two times per day and aspirin 100 mg once daily
Study: 34021038
Drug: Non-study aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-study aspirin
Study: 34670132
Drug: Algorithm-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided treatment with escitalopram (AGT-E)
Study: 34670132
Drug: Algorithm-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided treatment with mirtazapine (AGT-M)
Study: 32234000
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of omeprazole enteric-coated tablet 20 mg
Study: 32234000
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of omeprazole
Study: 34224994
Drug: High-dose IFN-β
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN-β 1a (88 μg on days 1, 3, 6) + lopinavir/ritonavir (400 mg/100 mg twice a day for 10 days)
Study: 34224994
Drug: Low-dose IFN-β
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN-β 1a (44 μg on days 1, 3, 6) + lopinavir/ritonavir (400 mg/100 mg twice a day for 10 days)
Study: 34224994
Drug: High-dose IFN-β
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN-β 1a
Study: 34224994
Drug: Low-dose IFN-β
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN-β 1a
Study: 36107972
Drug: ICE (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE (450 g of -2°C ice slurry)
Study: 33950949
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) plus chemotherapy (Kang Ai injection, herbal decoction, Zhenqifuzheng capsules)
Study: 33864994
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received a training booklet about chemotherapy-induced fatigue)
Study: 34482505
Drug: Hydrogen-rich ultrapure
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich ultrapure water (HRW) 500 mg of nickel chloride kg‐1 soil for 14 days
Study: 34482505
Drug: Hydrogen-rich ultrapure
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich ultrapure water (HRW) 200 mg of nickel chloride kg‐1 soil for 14 days
Study: 32295442
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment
Study: 32939556
Drug: Glycine intake
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine intake (5-100 mg·kg‐1·d‐1) during late gestation
Study: 32939556
Drug: Glycine intake
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine intake (5-100 mg·kg‐1·d‐1) during midgestation
Study: 34226226
Drug: Oral furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral furosemide 80 mg/day (adjusted to 160 mg/day if urine volume < 400 mL/day after 2 weeks)
Study: 34348606
Drug: Standard evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard evidence-based therapies
Study: 32715937
Drug: Random Forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Forest (RF) classifier used to predict treatment effect perception based on primary endpoints and judges' evaluations.
Study: 32300002
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and relaxation techniques administered by non-specialist providers, with six individual sessions and two to six booster sessions.
Study: 32990206
Drug: Propofol monotherapy
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol monotherapy
Study: 36114653
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester supplementation (27 g per dose, thrice daily)
Study: 32149579
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 1,000 IU/day
Study: 32149579
Drug: Single 200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200,000 IU injection (equivalent to 2,000 IU/day)
Study: 32252707
Drug: Internet-delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Acceptance and Commitment Therapy (IACT)
Study: 32252707
Drug: Adjusting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusting treatment content and format based on participants' characteristics
Study: 32785986
Drug: Microneedling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling and 5-fluorouracil solution (group C)
Study: 33568383
Drug: Roxadustat (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (70 mg oral, thrice-weekly)
Study: 35969113
Drug: Milk oral
Normalized name: lytes/dextros/mvn/AA/ging/milk ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk oral immunotherapy (OIT)
Study: 37125490
Drug: SA4Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA4Ag vaccine
Study: 35137458
Drug: GnRH (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (37.5 µg of Lecirelin)
Study: 35137458
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mL of physiological saline solution)
Study: 34052828
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline 100 mg bid for 8 weeks
Study: 34981516
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (KO) - 7 capsules per day (1.27g n-3 PUFA)
Study: 34981516
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) - 5 capsules per day (1.44g n-3 PUFA)
Study: 33451627
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (1000 mg)
Study: 37215391
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (NSPT)
Study: 35876941
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml water
Study: 36206208
Drug: Community-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based occupational therapy intervention (COT-MHABI) over one year, 16 sessions on average.
Study: 32946836
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine candidate (0.5 mL administered intramuscularly on days 0, 7, and 30)
Study: 32946836
Drug: Placebo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccine (0.5 mL administered intramuscularly on days 0, 7, and 30)
Study: 32946836
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine candidate
Study: 33970752
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of fast-release melatonin
Study: 34999239
Drug: Single-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ivermectin 1200 μg/kg for 5 days (arm C)
Study: 34999239
Drug: Single-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ivermectin 600 μg/kg plus placebo for 5 days (arm B)
Study: 36075243
Drug: Brensocatib 25
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 25 mg once daily for 28 days
Study: 38362600
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy
Study: 35152573
Drug: Simple carotid
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple carotid endarterectomy (CEA) with conventional treatment (aspirin and clopidogrel)
Study: 33059356
Drug: LSD 25
Normalized name: LSD 25
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 25 µg
Study: 33059356
Drug: LSD 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 50 µg
Study: 37231080
Drug: LSD 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 100 µg
Study: 33059356
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg + LSD 200 µg
Study: 33059356
Drug: LSD (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (25-200 µg)
Study: 33188930
Drug: Hydroxychloroquine, specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, specific dosage and duration not available
Study: 33188930
Drug: Propensity score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propensity score methods, including g-computation and doubly robust estimators, specific details not available
Study: 34824100
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (hs-cTnT <5 ng/L at presentation)
Study: 34267331
Drug: Various ML
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various ML techniques (XGBoost, LightGBM, Catboost, Support vector machine (SVM), Logistic regression (LR))
Study: 35537533
Drug: Brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab 6 mg every 4 weeks
Study: 35537533
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 4 weeks
Study: 32404117
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (FiO2 = 0.6, inhaling PGE1 0.1 μg/kg)
Study: 32404117
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P and Group L
Study: 32404117
Drug: Group P,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P, Group L, and Group C
Study: 33608841
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg)
Study: 36828201
Drug: Everolimus (EVL)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Study: 32951744
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage for 15 minutes daily (Group A)
Study: 32951744
Drug: PEG 20g
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 20g daily (Group B)
Study: 32951744
Drug: PEG 20g
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 20g plus abdominal massage for 15 minutes daily (Group C)
Study: 35628840
Drug: Pre-emptive analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive analgesic acetaminophen (15 mg/kg)
Study: 33831899
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg bolus over 10 min followed by continuous infusion of 100 μg/kg/min)
Study: 34980867
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid and ezetimibe combination
Study: 33176703
Drug: Group-based multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based multicomponent high intensity exercise program led by a physiotherapist twice a week for 4 months.
Study: 36273203
Drug: HA-VTE risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates; additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025) including recommendations for pharmacologic prophylaxis if appropriate.
Study: 33172456
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser pre-treatment (energy 50-300 mJ, frequency 5-30 Hz)
Study: 33172456
Drug: Conventional acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acid etching treatment
Study: 33174761
Drug: Bare-metal stent
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stent plus 1 mg of colchicine for 3 months
Study: 33174761
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent alone
Study: 35183498
Drug: Isonicotinic acid
Normalized name: Isonicotinic acid
DrugBank: Isonicotinic acid (DB16884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonicotinic acid hydrazide (INH) 900 mg vaginally
Study: 34076966
Drug: CPT-11 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (60 mg/m2 on days 1 and 8) every three weeks
Study: 34076966
Drug: AMR (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR (35 mg/m2 on days 1–3) every three weeks
Study: 34536915
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium
Study: 35867857
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, single injection adductor canal block, plus five additional interventions: local anesthetic infiltration between the popliteal artery and capsule of the posterior knee, intraoperative intravenous dexmedetomidine and ketamine, one additional intravenous dexamethasone bolus, and two additional adductor canal block injections.
Study: 35867857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, and a single injection adductor canal block.
Study: 34914726
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011)
Study: 35338847
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day of n‐3 PUFA
Study: 35485357
Drug: HIIT (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT (5 x 1 min at 80-95% maximal heart rate, twice weekly for 12 weeks)
Study: 34075813
Drug: Apixaban dose
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban dose adjustment based on age, weight, and serum creatinine in NVAF.
Study: 34799501
Drug: Dexamethasone 3
Normalized name: dexamethasone 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 3 mg
Study: 33059195
Drug: Second-line medications
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line medications (inhaled pentamidine, dapsone, atovaquone)
Study: 34345969
Drug: Pre‐emptive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive antibiotic treatment with clarithromycin (200 mg twice per day) during panitumumab treatment.
Study: 33183576
Drug: Curcumin 1000
Normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1000 mg/day for 12 weeks
Study: 32208040
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment for esophageal GISTs
Study: 33559351
Drug: Stryphnodendron adstringens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stryphnodendron adstringens (SA) at 3000 mg/L
Study: 33559351
Drug: Lafoensia pacari
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafoensia pacari (LP) at 300 mg/L
Study: 33559351
Drug: Copaifera spp.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaifera spp. (CO) at 300 mg/L
Study: 33559351
Drug: Pterodon emarginatus
Normalized name: Malpighia emarginata seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterodon emarginatus (PE) at 30 and 300 mg/L
Study: 33559351
Drug: Stryphnodendron adstringens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stryphnodendron adstringens (SA) at 300 mg/L
Study: 33559351
Drug: Lafoensia pacari
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafoensia pacari (LP) at 30 mg/L
Study: 32960320
Drug: Selective retina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective retina therapy (SRT)
Study: 34377137
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora (ZM) extract syrup
Study: 32643674
Drug: SGB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB with 10 mL of 0.5% bupivacaine (Group B)
Study: 33818314
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy group (LLLT)
Study: 35837981
Drug: TOTUM-63 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOTUM-63 (5 g/day)
Study: 35213728
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users
Study: 33735707
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment for 16 weeks
Study: 33735707
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 16 weeks
Study: 32798835
Drug: Food-related behavioral
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-related behavioral activation therapy (F-BA)
Study: 34903983
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSS) 150 mL